Inibidores de SGLT-2 e agonistas do receptor de GLP-1: terapia combinada para melhores desfechos nos pacientes com DM?

Referências

1. Scheen AJ. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2  inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2018;143:88-100. doi:10.1016/j.diabres.2018.06.008

2. Giugliano D, Scappaticcio L, Longo M, Bellastella G, Esposito K. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off. Cardiovasc Diabetol. 2021;20(1):205. doi:10.1186/s12933-021-01400-9

3. Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2  diabetes mellitus. Nat Rev Endocrinol. 2020;16(10):556-577. doi:10.1038/s41574-020-0392-2

4. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022;145(9). doi:10.1161/CIR.0000000000001040

5. Tuttle KR. Digging deep into cells to find mechanisms of kidney protection by SGLT2  inhibitors. J Clin Invest. 2023;133(5). doi:10.1172/JCI167700

6. Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and  diabetes. lancet Diabetes Endocrinol. 2022;10(4):284-296. doi:10.1016/S2213-8587(22)00003-1

7. Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022;107(1):29-38. doi:10.1210/clinem/dgab578

8. Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia. 2021;(1). doi:10.1007/s00125-021-05442-2

9. Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis. Diabetes, Obes Metab. 2020;22(10):1857-1868. doi:10.1111/dom.14108